Complex | |
AACDB_ID: | 6796 |
PDBID: | 4EDW |
Chains: | HL_V |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.48 |
Reference: | 10.4161/mabs.28677 |
Antibody | |
Antibody: | Tanezumab Fab |
Antibody mutation: | No |
INN (Clinical Trial): | Tanezumab(Phase-III) |
Antigen | |
Antigen: | Nerve growth factor (NGF) |
Antigen mutation: | No |
Durg Target: | P01138 |
Antibody
Heavy Chain: H
Mutation: NULL
>4EDW_H|Chain C[auth H]|tanezumab Fab heavy chain|Homo sapiens (9606) QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKTSHHHHHHG |
Light Chain: L
Mutation: NULL
>4EDW_L|Chain B[auth L]|tanezumab Fab light chain|Homo sapiens (9606) DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: V
Mutation: NULL
>4EDW_V|Chain A[auth V]|Beta-nerve growth factor|Homo sapiens (9606) SSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
L: ASN31 TYR50 THR51 SER52 ARG53 PHE54 SER63 GLY64 SER65 GLY66 SER67 H: ILE30 GLY31 TYR32 ASP33 TRP52 GLY53 ASP54 THR56 TYR97 TRP98 TYR99 V: HIS8 ARG9 GLY10 GLU11 PHE12 SER13 SER17 VAL18 SER19 VAL20 TRP21 GLY23 ASP24 PHE49 LYS50 TYR52 PHE54 THR56 THR106 ALA107 CYS108 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)